FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma
On August 20, 2020, the Food and Drug Administration approved carfilzomib and daratumumab in combination…
Browsing: daratumumab
FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
The Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj for adult patients with newly…
ASH 2019: Triple drug combination delays disease progression in people with stubborn multiple myeloma
Adding daratumumab to carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma…
ASH 2019: Daratumumab shows overall survival benefit and continued improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are ineligible for transplant
The phase 3 ALCYONE study showed the addition of daratumumab to bortezomib, melphalan and prednisone (D-VMP) improved…
ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma
Interim results from a large international phase III clinical trial show that adding the immunotherapy…
First targeted therapy for multiple myeloma effective against hard-to-treat disease
ASH: Myeloma is cancer of the plasma cells, white blood cells that produce infection-fighting antibodies.…